SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

Sodium chloride 0.9% and potassium chloride 0.075% solution provides electrolyte replacement to maintain fluid and electrolyte balance. Sodium is the principal cation of extracellular fluid and maintains osmotic pressure and acid-base balance. Potassium is the principal intracellular cation and is essential for nerve impulse transmission, muscle contraction, and enzymatic reactions.

What the body does with it

Metabolism	Sodium is primarily excreted unchanged by the kidneys. Potassium is primarily excreted by the kidneys, with minimal extrarenal elimination.
Excretion	Renal: >95% of infused sodium and potassium ions are excreted unchanged in urine. Fecal and biliary routes are negligible (<5%).
Half-life	Sodium and potassium ions have distribution half-lives of ~20-30 minutes; elimination half-life is not applicable as they are freely filtered and reabsorbed to maintain homeostasis. Clinical context: Kinetics depend on renal function and hydration status.
Protein binding	Sodium: <1% bound to proteins; Potassium: negligible binding (<1%).
Volume of Distribution	Sodium: ~0.6 L/kg (total body water); Potassium: ~4 L/kg (predominantly intracellular). Clinical meaning: Sodium distributes in extracellular fluid, while potassium's Vd reflects intracellular uptake.
Bioavailability	Intravenous: 100% (only relevant route). Oral: sodium and potassium are absorbed but not applicable to this IV formulation.
Onset of Action	Intravenous infusion: immediate (<1 minute) for electrolyte and fluid expansion as the solution mixes with plasma.
Duration of Action	Depends on infusion rate and renal clearance; typically 1-2 hours for volume expansion effects, with electrolyte effects lasting until renal excretion adjusts balance. Clinical note: Continuous infusion may be needed for maintenance.

Classification & Brands

Dosing & administration

Intravenous infusion: 500-1000 mL as a single dose; rate determined by clinical needs, typically 2-4 mL/min. Maximum infusion rate 20 mEq K+/hour.

Dosage form	INJECTABLE
Renal impairment	GFR > 50 mL/min: no adjustment. GFR 30-50 mL/min: reduce potassium content to 0.0375% or use alternative. GFR < 30 mL/min: contraindicated due to potassium accumulation.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B/C: dose as per standard; monitor electrolytes closely due to risk of ascites and edema. No specific dose reduction required.
Pediatric use	Weight-based: 20-50 mL/kg per day for maintenance, maximum 100 mL/kg/day. Potassium chloride dose: 2-4 mEq/kg/day, not to exceed 3 mEq/kg/day. Rate: not to exceed 0.5-1 mEq K+/kg/hour.
Geriatric use	No specific dose reduction, but start at lower end of dosing range (e.g., 500 mL). Monitor for fluid overload, hyperkalemia, and renal function. Infusion rate: 2-4 mL/min or slower.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Sodium and potassium are normally present in breast milk; this solution does not significantly alter milk levels. M/P ratio not applicable. Considered compatible with breastfeeding.
Teratogenic Risk	No evidence of teratogenic risk. Sodium and potassium are normal physiological electrolytes. No fetal harm reported with therapeutic use. Trimester-specific risks: No increased risk in any trimester. High doses may cause electrolyte disturbances in mother and fetus.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warnings.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Hypernatremia","Severe renal impairment with oliguria or anuria","Fluid overload states (e.g., pulmonary edema, congestive heart failure)"]

Clinical Precautions

Precautions

["Use with caution in patients with renal impairment, heart failure, or conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, diabetes).","Monitor serum potassium levels during therapy, especially with rapid administration or prolonged use.","Avoid use in patients with hyperkalemia or fluid overload.","Risk of dilutional hyponatremia or hypernatremia depending on fluid balance."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

What the body does with it

Metabolism	Sodium is primarily excreted unchanged by the kidneys. Potassium is primarily excreted by the kidneys, with minimal extrarenal elimination.
Excretion	Renal: >95% of infused sodium and potassium ions are excreted unchanged in urine. Fecal and biliary routes are negligible (<5%).
Half-life	Sodium and potassium ions have distribution half-lives of ~20-30 minutes; elimination half-life is not applicable as they are freely filtered and reabsorbed to maintain homeostasis. Clinical context: Kinetics depend on renal function and hydration status.
Protein binding	Sodium: <1% bound to proteins; Potassium: negligible binding (<1%).
Volume of Distribution	Sodium: ~0.6 L/kg (total body water); Potassium: ~4 L/kg (predominantly intracellular). Clinical meaning: Sodium distributes in extracellular fluid, while potassium's Vd reflects intracellular uptake.
Bioavailability	Intravenous: 100% (only relevant route). Oral: sodium and potassium are absorbed but not applicable to this IV formulation.
Onset of Action	Intravenous infusion: immediate (<1 minute) for electrolyte and fluid expansion as the solution mixes with plasma.
Duration of Action	Depends on infusion rate and renal clearance; typically 1-2 hours for volume expansion effects, with electrolyte effects lasting until renal excretion adjusts balance. Clinical note: Continuous infusion may be needed for maintenance.

Classification & Brands

Dosing & administration

Intravenous infusion: 500-1000 mL as a single dose; rate determined by clinical needs, typically 2-4 mL/min. Maximum infusion rate 20 mEq K+/hour.

Dosage form	INJECTABLE
Renal impairment	GFR > 50 mL/min: no adjustment. GFR 30-50 mL/min: reduce potassium content to 0.0375% or use alternative. GFR < 30 mL/min: contraindicated due to potassium accumulation.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B/C: dose as per standard; monitor electrolytes closely due to risk of ascites and edema. No specific dose reduction required.
Pediatric use	Weight-based: 20-50 mL/kg per day for maintenance, maximum 100 mL/kg/day. Potassium chloride dose: 2-4 mEq/kg/day, not to exceed 3 mEq/kg/day. Rate: not to exceed 0.5-1 mEq K+/kg/hour.
Geriatric use	No specific dose reduction, but start at lower end of dosing range (e.g., 500 mL). Monitor for fluid overload, hyperkalemia, and renal function. Infusion rate: 2-4 mL/min or slower.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Sodium and potassium are normally present in breast milk; this solution does not significantly alter milk levels. M/P ratio not applicable. Considered compatible with breastfeeding.
Teratogenic Risk	No evidence of teratogenic risk. Sodium and potassium are normal physiological electrolytes. No fetal harm reported with therapeutic use. Trimester-specific risks: No increased risk in any trimester. High doses may cause electrolyte disturbances in mother and fetus.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warnings.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Hypernatremia","Severe renal impairment with oliguria or anuria","Fluid overload states (e.g., pulmonary edema, congestive heart failure)"]